Smartlens, Inc. Closes $6.1M Series A led by Ambit Health Ventures with investments from prominent institutions and Stanford University
Summary
MOUNTAIN VIEW, Calif., July 11, 2023 /PRNewswire/ -- Smartlens, Inc., a clinical-stage ophthalmic technology company, has closed an oversubscribed $6.1M Series A equity financing round to advance regulatory clearance for miLens, a novel, electronics-free, soft contact lens for monitoring diurnal intraocular pressure (IOP).The funding round was led by Ambit Health Ventures, joined by Stanford University, Graphene Ventures, Sophia Innovation Capital, Plaisance Capital Management, 3E Bioventures, Boutique Venture Partners and Wilson Sonsini Investments alongside doctors, industry veterans and key opinion leaders.At the 2023 American Glaucoma Society Annual Meeting, the Company revealed remarkable clinical results for miLens. From early diagnosis to comprehensive disease management, the utilization of this data can help prevent progression, while also offering tailored treatments for individuals at various stages of glaucoma. "Sam Goldberger MD, MBA Co-Founder and Managing Partner of Ambit Health Ventures said, "This technology is of the utmost importance in comprehending glaucoma and the daily fluctuations in intraocular pressure (IOP). Designed as an electronics-free, soft contact lens, miLens is the smallest wearable microfluidic device available.Smartlens, Inc. is an ophthalmic technology company specializing in developing innovative solutions for diagnosing and treating chronic eye diseases. With a strong focus on addressing unmet needs in ophthalmology, the companys pipeline includes cutting-edge technologies that will facilitate improved clinical decision-making while also paving the way for a new generation of therapies.